TAFRO syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:457077M35.8
Who is this for?
Show terms as
1Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

TAFRO syndrome is a rare and serious inflammatory disorder. Its name comes from the five main features of the disease: Thrombocytopenia (low platelet count), Anasarca (severe fluid buildup throughout the body), Fever, Reticulin fibrosis (scarring in the bone marrow), and Organomegaly (enlarged organs, especially the spleen and liver). TAFRO syndrome is considered a subtype or variant of idiopathic multicentric Castleman disease (iMCD), a group of conditions involving overgrowth of cells in the lymph nodes and widespread inflammation. The disease causes the immune system to become overactive, leading to a dangerous inflammatory response. Patients often experience sudden onset of high fevers, rapid fluid retention causing swelling in the abdomen and legs, very low platelet counts that can lead to bleeding, and kidney problems. The bone marrow shows a specific type of scarring called reticulin fibrosis. Blood tests typically show elevated inflammatory markers and low platelet counts, which helps distinguish TAFRO from other forms of Castleman disease where platelets are usually high. Treatment focuses on calming the overactive immune system and managing symptoms. Doctors commonly use corticosteroids (like dexamethasone or methylprednisolone) as a first step, often combined with other immunosuppressive drugs. Tocilizumab, a drug that blocks the inflammatory protein interleukin-6, and rituximab, which targets certain immune cells, have shown benefit in many patients. Some patients require intensive care during severe flares. The disease can follow a relapsing course, meaning it may come back after treatment, and some cases can be life-threatening if not treated promptly.

Also known as:

Key symptoms:

Low platelet count leading to easy bruising or bleedingSevere swelling throughout the body, especially in the abdomen and legsPersistent high feversEnlarged spleenEnlarged liverKidney problems or kidney failureFluid buildup in the abdomen (ascites)Fluid around the lungs (pleural effusion)Extreme fatigue and weaknessSwollen lymph nodesBone marrow scarringElevated inflammatory blood markersLow blood pressure during flaresWeight gain from fluid retentionSmall or normal-sized lymph nodes (unlike typical Castleman disease)

Clinical phenotype terms (25)— hover any for plain English
AnasarcaHP:0012050Increased megakaryocyte countHP:0005513MyelofibrosisHP:0011974Increased circulating interleukin 6 concentrationHP:0030783Elevated vascular endothelial growth factor levelHP:0031052Reduced circulating lactate dehydrogenase concentrationHP:0045041
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Jun 2021Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi

UNC Lineberger Comprehensive Cancer Center — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for TAFRO syndrome.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
Phase 21 trial
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
Phase 2
Active
PI: Matthew Painschab, MD (University of North Carolina) · Sites: Lilongwe · Age: 1899 yrs

No specialists are currently listed for TAFRO syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to TAFRO syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open TAFRO syndromeForum →

No community posts yet. Be the first to share your experience with TAFRO syndrome.

Start the conversation →

Latest news about TAFRO syndrome

No recent news articles for TAFRO syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my case of TAFRO syndrome, and which organs are currently affected?,What treatment plan do you recommend, and what are the potential side effects?,How will we monitor for disease relapses, and what warning signs should I watch for at home?,Are my kidneys affected, and if so, what can be done to protect them?,Should I see additional specialists, such as a nephrologist or rheumatologist?,Are there any clinical trials or newer treatments available for TAFRO syndrome?,What precautions should I take to prevent infections while on immunosuppressive therapy?

Common questions about TAFRO syndrome

What is TAFRO syndrome?

TAFRO syndrome is a rare and serious inflammatory disorder. Its name comes from the five main features of the disease: Thrombocytopenia (low platelet count), Anasarca (severe fluid buildup throughout the body), Fever, Reticulin fibrosis (scarring in the bone marrow), and Organomegaly (enlarged organs, especially the spleen and liver). TAFRO syndrome is considered a subtype or variant of idiopathic multicentric Castleman disease (iMCD), a group of conditions involving overgrowth of cells in the lymph nodes and widespread inflammation. The disease causes the immune system to become overactive,

How is TAFRO syndrome inherited?

TAFRO syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does TAFRO syndrome typically begin?

Typical onset of TAFRO syndrome is adult. Age of onset can vary across affected individuals.

Are there clinical trials for TAFRO syndrome?

Yes — 1 recruiting clinical trial is currently listed for TAFRO syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.